Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand

Melvin A. Sarayba, Li Li, Tulaya Tungsiripat, Norman H. Liu, Paula M. Sweet, Anup J. Patel, Kathryn E. Osann, Amar Chittiboyina, Stephen C. Benson, Harrihar A. Pershadsingh, Roy S. Chuck

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose. To determine the efficacy of the peroxisome proliferator-activated receptor γ agonist, pioglitazone, in inhibiting corneal neovascularization. Methods. Twenty-six adult male Sprague-Dawley rats were randomly divided into three groups. Each group received intrastromal polymer micropellets containing one of the following: Group 1, no active ingredient (n=10); Group 2, vascular endothelial growth factor (VEGF) (n=7); Group 3, VEGF and pioglitazone (n=9). Neovascularization was evaluated 7 days after pellet implantation. After systemic India ink injection, digital photographs of the eyes were taken. The area and density of neovascularization were measured using imaging software. Results. Mean area of neovascularization was 0.43±0.18 mm2 for Group 1, 2.87±0.48 mm2 for Group 2 and 2.10±0.22 mm2 for Group 3. Statistical analysis showed significant differences between Groups 1 and 2 and Groups 1 and 3. There was no significant difference between Groups 2 and 3. Mean density of neovascularization was 2.16±0.66 for Group 1, 27.14±2.93 for Group 2 and 12.02±2.24 for Group 3. All comparisons between groups were statistically significant (P<0.01). Conclusions. Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. There is possibility of even greater effect with higher doses of the drug. Pioglitazone is a promising drug for the treatment of ocular neovascularization.

Original languageEnglish (US)
Pages (from-to)435-442
Number of pages8
JournalExperimental Eye Research
Volume80
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

pioglitazone
Corneal Neovascularization
Peroxisome Proliferator-Activated Receptors
Vascular Endothelial Growth Factor A
Ligands
Pharmaceutical Preparations
Cornea
Sprague Dawley Rats
Polymers
Software
Injections

Keywords

  • Cornea
  • Neovascularization
  • Pioglitazone
  • PPAR
  • Thiazolidinediones

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand. / Sarayba, Melvin A.; Li, Li; Tungsiripat, Tulaya; Liu, Norman H.; Sweet, Paula M.; Patel, Anup J.; Osann, Kathryn E.; Chittiboyina, Amar; Benson, Stephen C.; Pershadsingh, Harrihar A.; Chuck, Roy S.

In: Experimental Eye Research, Vol. 80, No. 3, 03.2005, p. 435-442.

Research output: Contribution to journalArticle

Sarayba, MA, Li, L, Tungsiripat, T, Liu, NH, Sweet, PM, Patel, AJ, Osann, KE, Chittiboyina, A, Benson, SC, Pershadsingh, HA & Chuck, RS 2005, 'Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand', Experimental Eye Research, vol. 80, no. 3, pp. 435-442. https://doi.org/10.1016/j.exer.2004.10.009
Sarayba, Melvin A. ; Li, Li ; Tungsiripat, Tulaya ; Liu, Norman H. ; Sweet, Paula M. ; Patel, Anup J. ; Osann, Kathryn E. ; Chittiboyina, Amar ; Benson, Stephen C. ; Pershadsingh, Harrihar A. ; Chuck, Roy S. / Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand. In: Experimental Eye Research. 2005 ; Vol. 80, No. 3. pp. 435-442.
@article{49f1d949af994aeeaf75d4c8116d31e3,
title = "Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand",
abstract = "Purpose. To determine the efficacy of the peroxisome proliferator-activated receptor γ agonist, pioglitazone, in inhibiting corneal neovascularization. Methods. Twenty-six adult male Sprague-Dawley rats were randomly divided into three groups. Each group received intrastromal polymer micropellets containing one of the following: Group 1, no active ingredient (n=10); Group 2, vascular endothelial growth factor (VEGF) (n=7); Group 3, VEGF and pioglitazone (n=9). Neovascularization was evaluated 7 days after pellet implantation. After systemic India ink injection, digital photographs of the eyes were taken. The area and density of neovascularization were measured using imaging software. Results. Mean area of neovascularization was 0.43±0.18 mm2 for Group 1, 2.87±0.48 mm2 for Group 2 and 2.10±0.22 mm2 for Group 3. Statistical analysis showed significant differences between Groups 1 and 2 and Groups 1 and 3. There was no significant difference between Groups 2 and 3. Mean density of neovascularization was 2.16±0.66 for Group 1, 27.14±2.93 for Group 2 and 12.02±2.24 for Group 3. All comparisons between groups were statistically significant (P<0.01). Conclusions. Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. There is possibility of even greater effect with higher doses of the drug. Pioglitazone is a promising drug for the treatment of ocular neovascularization.",
keywords = "Cornea, Neovascularization, Pioglitazone, PPAR, Thiazolidinediones",
author = "Sarayba, {Melvin A.} and Li Li and Tulaya Tungsiripat and Liu, {Norman H.} and Sweet, {Paula M.} and Patel, {Anup J.} and Osann, {Kathryn E.} and Amar Chittiboyina and Benson, {Stephen C.} and Pershadsingh, {Harrihar A.} and Chuck, {Roy S.}",
year = "2005",
month = "3",
doi = "10.1016/j.exer.2004.10.009",
language = "English (US)",
volume = "80",
pages = "435--442",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand

AU - Sarayba, Melvin A.

AU - Li, Li

AU - Tungsiripat, Tulaya

AU - Liu, Norman H.

AU - Sweet, Paula M.

AU - Patel, Anup J.

AU - Osann, Kathryn E.

AU - Chittiboyina, Amar

AU - Benson, Stephen C.

AU - Pershadsingh, Harrihar A.

AU - Chuck, Roy S.

PY - 2005/3

Y1 - 2005/3

N2 - Purpose. To determine the efficacy of the peroxisome proliferator-activated receptor γ agonist, pioglitazone, in inhibiting corneal neovascularization. Methods. Twenty-six adult male Sprague-Dawley rats were randomly divided into three groups. Each group received intrastromal polymer micropellets containing one of the following: Group 1, no active ingredient (n=10); Group 2, vascular endothelial growth factor (VEGF) (n=7); Group 3, VEGF and pioglitazone (n=9). Neovascularization was evaluated 7 days after pellet implantation. After systemic India ink injection, digital photographs of the eyes were taken. The area and density of neovascularization were measured using imaging software. Results. Mean area of neovascularization was 0.43±0.18 mm2 for Group 1, 2.87±0.48 mm2 for Group 2 and 2.10±0.22 mm2 for Group 3. Statistical analysis showed significant differences between Groups 1 and 2 and Groups 1 and 3. There was no significant difference between Groups 2 and 3. Mean density of neovascularization was 2.16±0.66 for Group 1, 27.14±2.93 for Group 2 and 12.02±2.24 for Group 3. All comparisons between groups were statistically significant (P<0.01). Conclusions. Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. There is possibility of even greater effect with higher doses of the drug. Pioglitazone is a promising drug for the treatment of ocular neovascularization.

AB - Purpose. To determine the efficacy of the peroxisome proliferator-activated receptor γ agonist, pioglitazone, in inhibiting corneal neovascularization. Methods. Twenty-six adult male Sprague-Dawley rats were randomly divided into three groups. Each group received intrastromal polymer micropellets containing one of the following: Group 1, no active ingredient (n=10); Group 2, vascular endothelial growth factor (VEGF) (n=7); Group 3, VEGF and pioglitazone (n=9). Neovascularization was evaluated 7 days after pellet implantation. After systemic India ink injection, digital photographs of the eyes were taken. The area and density of neovascularization were measured using imaging software. Results. Mean area of neovascularization was 0.43±0.18 mm2 for Group 1, 2.87±0.48 mm2 for Group 2 and 2.10±0.22 mm2 for Group 3. Statistical analysis showed significant differences between Groups 1 and 2 and Groups 1 and 3. There was no significant difference between Groups 2 and 3. Mean density of neovascularization was 2.16±0.66 for Group 1, 27.14±2.93 for Group 2 and 12.02±2.24 for Group 3. All comparisons between groups were statistically significant (P<0.01). Conclusions. Pioglitazone is effective in decreasing the density of angiogenesis in a VEGF-induced neovascular rat cornea model. There is possibility of even greater effect with higher doses of the drug. Pioglitazone is a promising drug for the treatment of ocular neovascularization.

KW - Cornea

KW - Neovascularization

KW - Pioglitazone

KW - PPAR

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=13844294425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844294425&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2004.10.009

DO - 10.1016/j.exer.2004.10.009

M3 - Article

VL - 80

SP - 435

EP - 442

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 3

ER -